Detecting breast cancer return early with a blood test and scans
Part of Cancer, Skin clinical trials.
This trial uses a simple blood test (liquid biopsy) and imaging to look for early signs that triple-negative breast cancer has returned after treatment. It is for people who had stage II or III cancer, went through chemotherapy before surgery, and still had cancer left after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with triple-negative breast cancer (your tumor has very little or no estrogen, progesterone, or HER2 receptors).
- Your original breast tumor was either larger than 2 cm (about the size of a grape) or had spread to at least one lymph node.
- You received chemotherapy (and possibly immunotherapy) before surgery, and after surgery tests still found a moderate or large amount of cancer (called residual disease).
- You do not have another cancer that might interfere with the study (minor skin or cervical cancers are okay), and you are not pregnant.
- Your kidney function is good enough (a simple blood test can confirm this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This study is testing a research tool that may help doctors choose the best treatment for people with advanced triple-negative breast cancer. You will have a biopsy and blood draw to help see how the tool works.
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.